Releases
Embecta Faces Class Action Over 57% Stock Plunge
A 57.8% collapse in Embecta’s stock price on May 5, 2026, has triggered a securities fraud class action lawsuit. Filed in the U.S. District Court for the District of New Jersey, the complaint accuses the medical device company of misleading shareholders regarding the market stability of its insulin pen needle portfolio.




















